Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2012

01-06-2012 | Original Article

Plasma Ghrelin Levels in Patients with Familial Mediterranean Fever

Authors: Zulfikar Polat, Guldem Kilciler, A. Melih Ozel, Muammer Kara, Murat Kantarcioglu, Ahmet Uygun, Sait Bagci

Published in: Digestive Diseases and Sciences | Issue 6/2012

Login to get access

Abstract

Background

Familial Mediterranean fever (FMF) is an auto-inflammatory disorder characterized by febrile attacks. Increased acute-phase reactants are characteristic during febrile attacks. Ghrelin is a natural G-protein that decreases secretion of pro-inflammatory cytokines and acts as anti-inflammatory agent. The aim of this study was to investigate whether there is any change in ghrelin levels and whether increases in ghrelin levels can be used as a marker in these patients.

Subjects and Methods

Thirty-seven male patients and 30 healthy men as a control group were included in the study. Blood samples were obtained for ghrelin measurements both before the attacks (pre-attack period; ghrelin 1 group) and during the attacks (ghrelin 2 group). Samples were kept at −80°C until the analysis was conducted and plasma ghrelin levels were measured using an immune-sorbent assay method.

Results

Mean ghrelin levels measured during the attacks were significantly higher (11.01 ± 4.78 pg/ml) as compared to pre-attack levels (5.78 ± 2.17 pg/ml; p < 0.001). Similarly, mean ghrelin levels measured in FMF patients during an attack were significantly different from that of the control group (6.57 ± 4.13 pg/ml; p < 0.001).

Conclusions

In this study, high ghrelin levels were measured during attacks in FMF patients. This finding is in line with previous results regarding the fact that inflammatory response arising during an FMF attack is an acute inflammatory event. Our findings suggest that ghrelin levels measured during FMF attacks could be used as a biochemical indicator for the FMF attack in FMF patients and that it could be used for support of the diagnosis of the disease.
Literature
1.
go back to reference Fonnesu C, Cerquaglia C, Giovinale M, et al. Familial Mediterranean fever: a review for clinical management. Joint Bone Spine. 2009;76:227–233.PubMedCrossRef Fonnesu C, Cerquaglia C, Giovinale M, et al. Familial Mediterranean fever: a review for clinical management. Joint Bone Spine. 2009;76:227–233.PubMedCrossRef
2.
go back to reference Tunca M, Akar S, Onen F, Turkish FMF Study Group, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine. 2005;84:1–11.PubMedCrossRef Tunca M, Akar S, Onen F, Turkish FMF Study Group, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine. 2005;84:1–11.PubMedCrossRef
3.
go back to reference Ben-Chetrit E. Familial Mediterranean fever (FMF) and renal AA amyloidosis—phenotype-genotype correlation, treatment and prognosis. J Nephrol. 2003;16:431–434.PubMed Ben-Chetrit E. Familial Mediterranean fever (FMF) and renal AA amyloidosis—phenotype-genotype correlation, treatment and prognosis. J Nephrol. 2003;16:431–434.PubMed
4.
go back to reference Lidar M, Livneh A. Familial Mediterranean fever: clinical, molecular and management advancements. Neth J Med. 2007;65:318–324.PubMed Lidar M, Livneh A. Familial Mediterranean fever: clinical, molecular and management advancements. Neth J Med. 2007;65:318–324.PubMed
5.
go back to reference Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–660.PubMedCrossRef Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–660.PubMedCrossRef
6.
go back to reference Papotti M, Ghe C, Cassoni P, et al. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab. 2000;85:3803–3807.PubMedCrossRef Papotti M, Ghe C, Cassoni P, et al. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab. 2000;85:3803–3807.PubMedCrossRef
7.
go back to reference Kojima M, Kangawa K. Structure and function of ghrelin. Results Probl Cell Differ. 2008;46:89–115.PubMedCrossRef Kojima M, Kangawa K. Structure and function of ghrelin. Results Probl Cell Differ. 2008;46:89–115.PubMedCrossRef
8.
go back to reference Kojima M, Kangawa K. Ghrelin, an orexigenic signaling molecule from the gastrointestinal tract. Curr Opin Pharmacol. 2002;2:665–668.PubMedCrossRef Kojima M, Kangawa K. Ghrelin, an orexigenic signaling molecule from the gastrointestinal tract. Curr Opin Pharmacol. 2002;2:665–668.PubMedCrossRef
9.
go back to reference Otero M, Nogueiras R, Lago F, Dieguez C, Gomez-Reino JJ, Gualillo O. Chronic inflammation modulates ghrelin levels in humans and rats. Rheumatology. 2004;43:306–310.PubMedCrossRef Otero M, Nogueiras R, Lago F, Dieguez C, Gomez-Reino JJ, Gualillo O. Chronic inflammation modulates ghrelin levels in humans and rats. Rheumatology. 2004;43:306–310.PubMedCrossRef
10.
go back to reference Li WG, Gavrila D, Liu X, et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation. 2004;11:2221–2226.CrossRef Li WG, Gavrila D, Liu X, et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation. 2004;11:2221–2226.CrossRef
11.
go back to reference Ozel AM, Demirturk L, Aydogdu A, et al. Effect of Helicobacter pylori infection and eradication therapy on interleukin-6 levels in patients with familial Mediterranean fever. Int J Clin Pract. 2008;62:754–761.PubMedCrossRef Ozel AM, Demirturk L, Aydogdu A, et al. Effect of Helicobacter pylori infection and eradication therapy on interleukin-6 levels in patients with familial Mediterranean fever. Int J Clin Pract. 2008;62:754–761.PubMedCrossRef
12.
go back to reference Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40:1879–1885.PubMedCrossRef Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40:1879–1885.PubMedCrossRef
13.
go back to reference Koca SS, Ozgen M, Aydin S, et al. Ghrelin and obestatin levels in rheumatoid arthritis. Inflammation. 2008;31:329–335.PubMedCrossRef Koca SS, Ozgen M, Aydin S, et al. Ghrelin and obestatin levels in rheumatoid arthritis. Inflammation. 2008;31:329–335.PubMedCrossRef
14.
go back to reference Yalniz M, Bahcecioglu IH, Ataseven H, et al. Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis. Mediat Inflamm. 2006;6:34295. Yalniz M, Bahcecioglu IH, Ataseven H, et al. Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis. Mediat Inflamm. 2006;6:34295.
15.
go back to reference Vila G, Maier C, Riedl M, et al. Bacterial endotoxin induces biphasic changes in plasma ghrelin in healthy humans. J Clin Endocrinol Metab. 2007;92:3930–3934.PubMedCrossRef Vila G, Maier C, Riedl M, et al. Bacterial endotoxin induces biphasic changes in plasma ghrelin in healthy humans. J Clin Endocrinol Metab. 2007;92:3930–3934.PubMedCrossRef
16.
go back to reference Yilmaz Z, Ilcol YO, Ulus IH. Endotoxin increases plasma leptin and ghrelin levels in dogs. Crit Care Med. 2008;36:828–833.PubMedCrossRef Yilmaz Z, Ilcol YO, Ulus IH. Endotoxin increases plasma leptin and ghrelin levels in dogs. Crit Care Med. 2008;36:828–833.PubMedCrossRef
17.
go back to reference Wu R, Dong W, Zhou M, et al. Ghrelin improves tissue perfusion in severe sepsis via downregulation of endothelin-1. Cardiovasc Res. 2005;68:318–326.PubMedCrossRef Wu R, Dong W, Zhou M, et al. Ghrelin improves tissue perfusion in severe sepsis via downregulation of endothelin-1. Cardiovasc Res. 2005;68:318–326.PubMedCrossRef
18.
go back to reference Chang L, Du JB, Gao LR, Pang YZ, Tang CS. Effect of ghrelin on septic shock in rats. Acta Pharmacol Sin. 2003;24:45–49.PubMed Chang L, Du JB, Gao LR, Pang YZ, Tang CS. Effect of ghrelin on septic shock in rats. Acta Pharmacol Sin. 2003;24:45–49.PubMed
19.
go back to reference Kodama T, Ashitani J, Matsumoto N, Kangawa K, Nakazato M. Ghrelin treatment suppresses neutrophil-dominant inflammation in airways of patients with chronic respiratory infection. Pulm Pharmacol Ther. 2008;21:774–779.PubMedCrossRef Kodama T, Ashitani J, Matsumoto N, Kangawa K, Nakazato M. Ghrelin treatment suppresses neutrophil-dominant inflammation in airways of patients with chronic respiratory infection. Pulm Pharmacol Ther. 2008;21:774–779.PubMedCrossRef
20.
go back to reference Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes. 2001;50:227–232.PubMedCrossRef Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes. 2001;50:227–232.PubMedCrossRef
Metadata
Title
Plasma Ghrelin Levels in Patients with Familial Mediterranean Fever
Authors
Zulfikar Polat
Guldem Kilciler
A. Melih Ozel
Muammer Kara
Murat Kantarcioglu
Ahmet Uygun
Sait Bagci
Publication date
01-06-2012
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2012
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2049-z

Other articles of this Issue 6/2012

Digestive Diseases and Sciences 6/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine